Webinars and Videos

Sufficiency, UPC second medical use claims, description amendments ǀ European biotech patent case law series (November 2026)

European patent attorneys Simon O'Brien and Matthew Caines present the latest instalment in D Young & Co's ongoing series examining significant developments in European Patent Office (EPO) biotechnology patent case law.

In this webinar, Simon and Matthew explore recent EPO Board of Appeal decisions affecting the protection of biotechnology and life sciences inventions, with practical insights for patent applicants, in-house counsel, researchers, and IP professionals.

  • Broadcast: 10 November 2026
  • Format: On-demand webinar
  • Duration: 60 minutes

Topics covered

T 0251/25 – sufficiency: credibility of claimed therapeutic effect

Jurisdiction: EPO
Decision level: Technical Board of Appeal
Citation: T 0251/25
Date: 29 June 2026 (online on 29 September 2026)

UPC-CFI-0001587/2025 – UPC decision on second medical use claims – patient subgroups

Jurisdiction: UPC
Decision level: Milan Central Division
Citation: UPC-CFI-0001587/2025
Date: 09 October 2026

G 1/25 – description amendments – a brief update

Jurisdiction: EPO
Decision level: Enlarged Board of Appeal
Citation: G 0001/25
Date: 03 September 2026

By watching this webinar, you will gain:

  • An understanding of recent EPO biotechnology patent case law developments.
  • Practical guidance on demonstrating technical effects in patent applications.
  • Insights into decisions from the Technical and Enlarged Board of the EPO, and UPC.
  • Strategic considerations for drafting and prosecuting life sciences and biotechnology patent applications before the EPO.
     

Speakers

Simon O'Brien is a partner and European patent attorney at D Young & Co. His practice covers biotechnology, molecular biology, diagnostics, pharmaceuticals, food technology and nutrition. He has extensive experience in EPO oppositions and appeals, manages international patent portfolios and regularly lectures on life sciences patent law. Simon is also the founder and host of D Young & Co's Biotechnology European Patent Case Law webinar series.

Matthew Caines is a partner and Chartered and European patent attorney at D Young & Co. With a strong scientific background spanning molecular biology, microbiology and immunology, he advises clients on securing and defending patent protection for biotechnological and chemical innovations. He has extensive experience in European patent prosecution, oppositions, appeals and freedom-to-operate matters, supporting clients from early-stage ventures through to multinational organisations. Prior to joining D Young & Co, Matthew conducted research at the University of Oxford, the MRC Laboratory of Molecular Biology and the University of British Columbia, and has published extensively in peer-reviewed scientific journals.

Who should watch?

This webinar is relevant to patent attorneys, in-house IP counsel, biotech and pharmaceutical companies, university technology transfer teams, R&D professionals, and anyone involved in protecting biotechnology and life sciences innovations in Europe. It will be particularly valuable for those working in biotechnology, pharmaceuticals, diagnostics, antibodies, gene editing technologies, RNA-based therapeutics, vaccines, viral vectors, immunology, molecular genetics and other life sciences sectors seeking to understand recent EPO case law.

About this series

This webinar forms part of D Young & Co's ongoing Biotechnology European Patent Case Law series, providing regular updates and practical analysis of important EPO decisions affecting the life sciences sector. 

System requirements

To view our webinars we recommend the following internet browsers:

  • Google Chrome (most recent 2 versions).
  • Mozilla Firefox (most recent 2 versions).
  • Apple Safari (most recent 2 versions).
  • Microsoft Edge (most recent 2 versions).
Patent newsletter Latest edition
Patent newsletter Latest edition